Skip to main content
Log in

Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: a “useless intraoperative fever” or the next hot voice in the surgical management of the “silent killer”?

  • News and Views
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

The aim of our opinion letter is to highlight the recent findings in the field of hyperthermic intraperitoneal chemotherapy (HIPEC) use in ovarian cancer management. Two recent studies reveal that ovarian cancer patients treated with HIPEC can extend their survival independently of the timing offered—either at the initial cytoreductive effort or at the time of disease relapse. The research field is flourishing and further data are awaited from randomised control trials. Although, HIPEC is not considered yet as the standard of care in the management of ovarian cancer patients, the initial findings of its use are promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240

    Article  PubMed  Google Scholar 

  2. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575

    Article  CAS  PubMed  Google Scholar 

  3. Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J (2016) Statement of the AGO Kommission Ovar, AGO study group, NOGGO, AGO Austria and AGO Switzerland regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Geburtshilfe Frauenheilkd 76(2):147–149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Vergote I, Chiva L, du Bois A (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1362–1363

    Article  PubMed  Google Scholar 

  5. Ceresoli M, Frigerio L, Ansaloni L (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1363

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

CI concept, data analysis, writing. JS concept, data analysis, writing, supervision

Corresponding author

Correspondence to C. Iavazzo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iavazzo, C., Spiliotis, J. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: a “useless intraoperative fever” or the next hot voice in the surgical management of the “silent killer”?. Arch Gynecol Obstet 298, 673–674 (2018). https://doi.org/10.1007/s00404-018-4877-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-018-4877-3

Navigation